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Considerable effort has been spent identi-
fying prognostic biomarkers in classic
Hodgkin lymphoma (cHL). The aim of our
study was to search for possible prognos-
tic parameters in advanced-stage cHL
using a proteomics-based strategy. A to-
tal of 14 cHL pretreatment tissue samples
from younger, advanced-stage patients were
included. Patients were grouped according
to treatment response. Proteins that were
differentially expressed between the groups
were analyzed using 2D-PAGE and identi-
fied by liquid chromatography mass spec-
trometry. Selected proteins were validated
using Western blot analysis. One of the
differentially expressed proteins, the
carbohydrate-binding protein galectin-1
(Gal-1), was further analyzed using immuno-
histochemistry HC and its expression was
correlated with clinicopathologic and out-
come parameters in 143 advanced-stage
cHL cases.At the univariate level, high Gal-1
expression in the tumor microenvironment
was correlated with poor event-free survival
(P .02). Among younger (< 61 years) pa-
tients, high Gal-1 was correlated with poorer
overall and event-free survival (both
P .007). In this patient group and at the
multivariate level, high Gal-1 expression re-
tained a significant predictive impact on
event-free survival. Therefore, in addition to
its functional role in cHL-induced immuno-
suppression, Gal-1 is also associated with
an adverse clinical outcome in this disease.
(Blood. 2011;117(24):6638-6649)
Introduction
The tumor lesion in classic Hodgkin lymphoma (cHL) is character-
ized by the presence of the typical Hodgkin and Reed-Sternberg
(HRS) tumor cells, largely outnumbered by nonneoplastic inflam-
matory bystanders that include B and T lymphocytes (predomi-
nantly Th2-type and FoxP3 regulatory T cells), macrophages,
eosinophils, basophils, and plasma cells.1
Over the past decades, the treatment of cHL has improved
considerably, and current therapeutic strategies succeed in curing
 80% of patients. However, 20%-30% still experience relapse or
refractory disease, many subsequently succumbing to death as a
result of either treatment complications or disease progression.2
Prompted by observations in other lymphoma subtypes such as
follicular lymphoma,3 increased attention has been drawn to the
possible biologic role and prognostic significance of the tumor-
infiltrating inflammatory cells in cHL. Several recent studies have
focused on this area, using gene-expression profiling to identify
new prognostic markers in cHL.4,5 Although these studies have led
to the identification of several candidate genes, no specific biologic
marker has yet been introduced as a reliable tool for pretherapeutic
risk assessment.
Several factors may influence the proteomic machinery and
affect the final properties of the encoded protein at several levels:
translational inhibition/activation, posttranslational modifications,
inhibition/activation of the proteins, specific degradations, etc.
Consequently, there can be considerable discrepancy between the
expression level of RNA and that of the corresponding protein
product.6 Therefore, proteomics-based approaches have recently
been used in HL to identify protein patterns that may provide
pathogenetic and prognostic clues.7,8 However, these studies were
only performed in cell lines and still await confirmation in an
in vivo setting.
Galectin-1 (Gal-1), a member of a growing family of animal
lectins with affinity to poly-N-acetyllactosamine–enriched glyco-
conjugates, has recently emerged as a regulator of inflammatory
responses, angiogenesis, and tumor progression.9,10 This glycan-
binding protein has been identified as a critical mediator of the
immunosuppressive activity of cHL because it is responsible for
creating the Th2/regulatory T cell–skewed microenvironment typi-
cal of the disease.11,12 Moreover, the combination of Gal-1 and
c-Jun has been proposed as a diagnostic biomarker for distinguish-
ing cHL from other lymphomas with shared morphologic and
molecular features.13
The aim of the present study was to provide data from an “in
vivo” setting by identifying differentially expressed proteins in
primary diagnostic tissue samples from treatment-sensitive versus
treatment-refractory cHL patients. This study constitutes the first
approach seeking to correlate protein expression, as assessed by
proteomics, with treatment response and clinical outcome in
advanced-stage cHL. Protein expression was evaluated in both the
neoplastic and nonneoplastic compartments of tumor biopsies.
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Methods
Patients
A total of 14 cHL pretreatment tissue samples were selected for 2D-PAGE
and liquid chromatography–tandem mass spectrometry (LC-MS/MS). The
tissue samples were embedded in optimal cutting temperature medium
(Tissue-Tek; Sakura) compound, snap-frozen in isopentane in liquid
nitrogen at the time of diagnosis, and stored at80°C.
On the basis of responses to initial treatment, 2 patient cohorts were
identified. The clinical features of these patients are detailed in Table 1. One
cohort was characterized by a favorable treatment response, defined as a
sustained complete remission for a minimum of 36 months. The second was
characterized by an unfavorable response to treatment, defined as either
progressive/refractory disease or relapse within a year after the end of
first-line therapy. To maximize comparability between the 2 cohorts in
terms of protein expression, patients in the 2 groups were matched with
regard to age (range 20-35 vs 14-51, median 24 vs 27 years; P  .52),
clinical stage (IB, IIB, III, or IV), and cHL histology (nodular sclerosis or
mixed cellularity). The workflow is outlined in Figure 1.
Where possible, data generated from the proteomic analysis were
validated in a cohort of 143 cHL patients using immunohistochemistry
(IHC) on tissue microarrays (TMAs) constructed from formalin-fixed,
paraffin-embedded primary pretreatment tumor biopsies (Table 3). Clinical
and follow-up data were obtained from clinical records. For deceased
patients, the precise date of death was obtained from the Danish Civil
Registration System. All primary diagnostic tumor biopsies were reviewed
and reclassified according to the World Health Organization classification
of tumors of the hematopoietic and lymphoid tissues.14 The patients were
treated at Aarhus University Hospital (Denmark) between 1990 and
2007 according to standard guidelines. Patients were uniformly treated with
“ABVD/COPP” (Adriamycin, bleomycin, vinblastine, dacarbazine/cyclo-
phosphamide, vincristine, procarbazine, and prednisone) chemotherapy.
Additional radiotherapy was given in case of pretherapeutic bulk or
localized residual masses. Treatment response was assessed using standard-
ized guidelines.15 The study was approved by the Regional Ethical
Committee and by the Danish Data Protection Agency.
Sample collection and preparation
From each cHL sample, a total of 70 sections of 20 m were cut and
transferred into empty Eppendorf tubes. H&E stains were made before and
after this process to ensure the presence of HRS cells throughout the
samples. Subsequently, 350 L of 3-10 NL lysis buffer containing 9M urea,
2% (wt/vol) Triton X-100, 2% (wt/vol) DTT, and 2% (vol/wt) IPG-buffer
(Amersham) were added to the cut sections.
Determination of total protein content
To ensure loading of equal protein amounts for both 2D-PAGE and 1D
Western blotting (WB), the protein concentration was determined using a
noninterfering assay (488250; Calbiochem).
2D-PAGE
The 2D-PAGE procedure was performed essentially as described previ-
ously16,17 with a few modifications. In summary, 100 g of protein was
Table 1. Clinical characteristics of patients selected for proteome comparison
No. Age, y Histology Ann Arbor stage B symptoms Treatment Outcome
1 21 MC III absent ABVD FR
2 24 NS II present ABVD/COPP  RT FR
3 24 NS IV present ABVD/COPP FR
4 26 NS II present ABVD/COPP  RT FR
5 35 NS III absent ABVD  RT FR
6 20 NS III present ABVD/COPP  RT FR
7 25 NS III present ABVD/COPP  RT FR
8 51 cHL-NOS I present ABVD/COPP  RT UR
9 41 NS IV present ABVD/COPP  RT UR
10 14 NS III present ABVD/COPP UR
11 21 NS II present ABVD/COPP UR
12 27 NS II present ABVD/COPP UR
13 33 NS IV present ABVD UR
14 23 NS III present ABVD/COPP  RT UR
FR indicates favorable response; UR, unfavorable response; MC, mixed cellularity; NS, Nodular sclerosis; NOS, not otherwise specified; and RT, radiotherapy.
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Figure 1. Flowchart describing the 2-step study strategy. Shown is the training-set
analysis followed by the validation-set analysis. IHC indicates immunohistochemistry.
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Table 2. List of identified proteins
Spot
no. Identified peptides Protein name
SwissProt
accession
Size,
kDa
Mascot
score Biological processes†
pH 3–10
1507 DREVGIPPEQSLETAK
EFNKYDTDGSK
Actin-related protein 3 ARP3_HUMAN 47.4 77 Cellular component movement, regulation
of actin filament polymerization, activation
of dendrite morphogenesis, regulation of
myosin II filament assembly or
disassembly, response to antibiotic
2002 DGGVQACFSRSR Guanine nucleotide-binding
protein G(k) subunit alpha
GNAI3_HUMAN 40.5 24‡ G-protein–coupled receptor protein
signaling pathway, negative regulation of
adenylate cyclase activity, negative
regulation of synaptic transmission, signal
transduction, vesicle function
2102 VRGEVAPDAK
FNAHGDANTIVCNSK
Galectin-1 LEG1_HUMAN 14.7 154 Activation of I-kB kinase/NF-kB cascade,
apoptotic programmed cell, death, cellular
response to glucose stimulus, multicellular
organismal response to stress, myoblast
cell differentiation, negative regulation of
cell-substrate adhesion
3102 QEYDESGPSIVHR Actin§ ACTB_HUMAN 42 86 Blood coagulation, platelet activation,
platelet degranulation
3107 TCVADESAENCDK Serum albumin ALBU_HUMAN 69.4 23‡ Transport, negative regulation of
programmed cell death and apoptosis,
maintenance of mitochondrial location,
cellular response to starvation
3107 HHEASSRADSSR Filaggrin FILA_HUMAN 435 32 Keratinocyte differentiation, multicellular
organismal development
4103 GSPAINVAVHVFR Transthyretin TTHY_HUMAN 16 96 Transport
4302* AGVETTTPSK Ig lambda chain C regions LAC_HUMAN 11.3 65 Involved in immune response
4302* QEYDESGPSIVHR Actin§ ACTB_HUMAN 42 87 Blood coagulation, platelet activation,
platelet degranulation
4502 DSYVGDEAQSK
DSYVGDEAQSKR
VAPEEHPVLLTEAPLNPK
LCYVALDFEQEMATAASSSSLEK
SYELPDGQVITIGNER
DLYANTVLSGGTTMYPGIADR
QEYDESGPSIVHR
Actin§ ACTG_HUMAN 42 601 Adherens junctions organization, axon
guidance, cell junction assembly, cell-cell
junction organization, cellular component
movement, response to calcium ion
5402 LIAPVAEEEATVPNNK
SLADELALVDVLEDK VIGSGCNLDSAR
LKDDEVAQLKK
L-lactate dehydrogenase B
chain
LDHB_HUMAN 37 298 Cellular carbohydrate metabolic process,
glycolysis, lactate metabolic process
NAD metabolic process,
oxidation-reduction process, pyruvate
metabolic process
5403 IEDGNNFGVAVQEK
QPHVGDYR
Proteasome activator
complex subunit 1
PSME1_HUMAN 28.7 136 Regulation of ubiquitin-protein ligase
activity involved in mitotic cell cycle,
proteasomal ubiquitin-dependent protein
catabolism
5604* DSYVGDEAQSK
DSYVGDEAQSKR
Actin§ ACTA_HUMAN 42 85 Muscle contraction, regulation of blood
pressure, response to virus, vascular
smooth muscle contraction
5604* ALLQAILQTEDMLK
ETQSQLETER
Desmoplakin DESP_HUMAN 331.8 37 Adherens junction organization, cell-cell
adhesion, development of epidermis,
keratinocyte differentiation, peptide
cross-linking, wound healing
5708 AAPEASGTPSSDAVSR Coronin-1A COR1A_HUMAN 51.0 52 Actin modulating activity, calcium ion
transport, cell-substrate adhesion, cell
movement, involved in immune response
(T cell response, T cell homeostasis,
leukocyte chemotaxis, phagocytosis),
regulation of cell shape
6002 VHLTPEEK
VNVDEVGGEALGR
Hemoglobin subunit beta HBB_HUMAN 16.0 105 Nitric oxide transport, oxygen transport,
regulation of nitric oxide biosynthesis,
regulation of blood pressure, regulation of
blood vessel size
*LC-MS/MS and subsequent search in the Swiss-Prot database resulted in more than one possible protein identification.
†Biological processes are taken from the Gene Ontology (GO) annotation system.
‡Identifications are significant when searches were performed in the human part of the SwissProt database.
§Several actin isoforms can be identified from the peptides.
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used from each sample. Isoelectric focusing was performed using 18-cm pH
3-10 or pH 4-7 nonlinear IPG strips. The IPG strips were rehydrated
overnight ( 20 hours) in 150 L of rehydration solution containing 8M
urea, 2% (wt/vol) CHAPS, 0.3% (wt/vol) DTT, 2% (vol/wt) IPG-buffer, and
bromphenol blue together with the 100-g protein sample in 200 L of
3-10 NL lysis buffer in a Immobiline DryStrip Reswelling Tray. After
rehydration, the samples were run at 500 V for 1 minute, 500 V for 5 hours,
and 3500 V for 14.5 hours in a Multiphor II system (PerkinElmer) in a
gradient mode at 17°C (MultiTemp III Thermostatic Circulator; GE
Healthcare Life Sciences). The IPG strips were equilibrated twice: first
in 20 mL of equilibration buffer consisting of 0.6% (wt/vol) Tris-HCl
(pH 6.8), 6M urea, 30% (vol/vol) glycerol, 1% (wt/vol) SDS, and 0.05%
(wt/vol) DTT, and then in 4.5% (wt/vol) iodoacetamide and bromophe-
nol blue. For the second dimension, 12% SDS-PAGE gels were run at
50 V overnight ( 20 hours), and transferred to fixation solution
containing 50% ethanol, 12% acetic acid, and 0.05% formaldehyde for a
minimum of 1 hour.
Silver staining
To visualize the proteins separated by 2D-PAGE, we used the Vorum
protocol as described previously.18 Gels were washed 3 times for 20 min-
utes each in 35% ethanol, then pretreated for 2 minutes in 0.02%
Na2S2O3;5H2O and washed in water 3 times for 3 minutes each. The gels
were stained with 0.2% AgNO3 and 0.028% formaldehyde for 20 minutes.
Gels were then rinsed twice in water for 1 minute, developed in 6%
Na2CO3, 0.0185% formaldehyde, 0.0004% Na2S2O3;5H2O, and the reaction
was stopped using 40% (vol/vol) ethanol and 12% (vol/vol) acetic acid.
This solution was changed once and the gels were dried between cellophane
sheets and sealed.
Data analysis
Two analyses were performed with first-dimension separation using
isoelectric focusing at either pH 3-10 or pH 4-7. Thirteen patients were
included in each analysis. (pH 3-10: patients 27, 35, 69, 79, 138, 174, 182,
Table 2. (continued)
Spot
no. Identified peptides Protein name
SwissProt
accession
Size,
kDa
Mascot
score Biological processes†
8103 AGAHLQGGAK Glyceraldehyde-3-phosphate
dehydrogenase
G3P_HUMAN 36 39 Glucose metabolism, glycolysis, oxidation,
and reduction processes
8206 ATAVMPDGQFK Peroxiredoxin 1 PRDX1_HUMAN 22.1 30 Cell, proliferation, cell redox homeostasis,
erythrocyte homeostasis, hydrogen
peroxide catabolic process, NK cell
mediated cytotoxicity, oxidation and
reduction processes, regulation of NF-
kappaB import into nucleus, regulation of
stress-activated MAPK cascade, removal
of superoxide radicals, skeletal system
development
8208* IGHPAPNFK
ATAVMPDGQFK
QITVNDLPVGR
Peroxiredoxin 1 PRDX1_HUMAN 22.1 25‡ Cell, proliferation, cell redox homeostasis,
erythrocyte homeostasis, hydrogen
peroxide catabolic process, NK cell
mediated cytotoxicity, oxidation and
reduction processes, regulation of NF-kB
import into nucleus, regulation of stress-
activated MAPK cascade, removal of
superoxide radicals, skeletal system
development
8208* AGVETTTPSK Ig lambda chain C regions LAC_HUMAN 11.3 32‡ Involved in immune response
9002 DLYANTVLSGGTTMYPGIADR Actin§ ACTB_HUMAN 42 99 Blood coagulation, platelet activation,
platelet degranulation
9201 LVINGNPITIFQER
AGAHLQGGAK
IISNASCTTNCLAPLAK
Glyceraldehyde-3-phosphate
dehydrogenase
G3P_HUMAN 36 186 Glucose metabolism, glycolysis, oxidation
and reduction processes
pH 4–7
7505 TCVADESAENCDK
ETYGEMADCCAK
AAFTECCQAADK
Serum albumin ALBU_HUMAN 69.4 182 Transport, negative regulation of
programmed cell death and apoptosis,
maintenance of mitochondrial location,
cellular response to starvation
3105 GCITIIGGGDTATCCAK Phosphoglycerate kinase 1 PGK1_HUMAN 45 55 Carbohydrate metabolic process,
gluconeogenesis, glucose metabolic
process, glycolysis, phosphorylation
3505 VAPEEHPVLLTEAPLNPK Actin§ ACTB_HUMAN 42 60 Blood coagulation, platelet activation,
platelet degranulation
3704 SYELPDGQVITIGNER Actin§ ACTA_HUMAN 42 56 Muscle contraction, regulation of blood
pressure, response to virus, vascular
smooth muscle contraction
7301 VAPEEHPVLLTEAPLNPK Actin§ ACTB_HUMAN 42 73 Blood coagulation, platelet activation,
platelet degranulation
*LC-MS/MS and subsequent search in the Swiss-Prot database resulted in more than one possible protein identification.
†Biological processes are taken from the Gene Ontology (GO) annotation system.
‡Identifications are significant when searches were performed in the human part of the SwissProt database.
§Several actin isoforms can be identified from the peptides.
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201, 243, 333, 415, 463, and 464; pH 4-7: patients 35, 69, 79, 138, 174, 182,
201, 243, 333, 415, 462, 463, and 464). The gels were scanned with a
GS-710 Calibrated Imaging Densitometer (Bio-Rad) using the Quantity
One software package Version 4.0.2. Gels were then imported into the
PDQuest Advanced 2D Gel Analysis Software Version 3.0 (Bio-Rad) that
assigned a volume to each spot proportional to the amount of protein. In
brief, the gels were normalized against the total density and, after
background subtraction, the spots were automatically defined and quanti-
fied. One gel in each study (pH 3-10: patient 79; pH 4-7: patient 464) was
chosen as a reference gel (master gel). In the reference gel, each spot was
assigned a number and all other gels were aligned to the reference gel and
all matched spots were numbered accordingly. All matches were critically
evaluated and the necessary editions and corrections were performed
manually. Spots that showed a significant (Mann-Whitney U test, P  .05)
and at least 2-fold differential expression were cut out of the gel and
subjected to in-gel tryptic digestion.
Protein identification by LC-MS/MS
Sample preparation and MS were performed essentially as described
previously.19 In brief, proteins were in-gel trypsinized overnight, pretreated
with acetonitrile, reduced with DTT, blocked with iodoacetamide, cleaved
by trypsin, and the peptides were extracted by 1 change of NH4HCO3 and
3 changes of formic acid in acetonitrile. Finally, the extracted peptides were
dried. The dried fragmented protein samples were dissolved in 6 L of
buffer A (97.7% H2O, 2% acetonitrile, and 0.3% formic acid). Peptide
separation before MS/MS analysis was performed using an inert nano-
liquid chromatography system (LC Packings). The samples were then
analyzed on a Q-TOF Premier mass spectrometer (Waters). The processed
data were used to search the Swiss-Prot Database (version 57.7, 57.8, or
2010_12 containing 497.293, 509.019, or 523.151 sequences, respectively)
or in a few cases the mammalian part (64 853 sequences) or the human part
(20 405 sequences) using the online version of the Mascot MS/MS Ion
Search facility (Matrix Science).20 Searching was performed with doubly
and triply charged ions with 2 missed cleavages, a peptide mass tolerance of
20 or 50 ppm, and an MS/MS tolerance of 0.05 Da.
Antibodies
The primary rabbit polyclonal anti–Gal-1 antibody generated in the
laboratory of one of the authors (G.A.R.) was described previously and
found to be specific for Gal-1 detection in cHL13 (WB dilution 1:100; IHC
dilution 1:5000). Other antibodies used were purchased from commercial
suppliers: anti-PSME1 (HPA006632; WB dilution 1:100, IHC dilution
1:400; ATLAS Antibodies), anti-GNAI3 (XW-7212; WB dilution 1:200
ProSci Incorporated), anti-Prdx1 (HPA007730; WB dilution 1:100, IHC
dilution 1:75; Atlas Antibodies), anti-FOXP3 (clone 236A/E7; dilution
1:50, Biocare Medical), anti–granzyme-B (clone GrB-7; dilution 1:20,
Dako), anti-CD68 (clone KP-1; dilution 1:800; Dako), anti-CD163 (clone
10D6; dilution 1:50, Novocastra), and anti-latent membrane protein-1
(anti–LMP-1; clones CS 1-4; dilution 1:100, Dako).
WB
WB was carried out in 11 or 12 of 14 patients from the cohort. One patient
per cohort could not be analyzed because of the limited amount of protein
left after the 2D-PAGE experiments. The same amount of protein was added
to each lane of the WBs used for one comparison, either 5 g per lane in the
case of Gal-1 or 10 g per lane in the case of guanine nucleotide-binding
protein G(k) subunit  (GNAI3), peroxiredoxin-1 (PRDX1), proteasome
activator complex subunit 1 (PSME2), and desmoplakin (DESP). The
samples were loaded on Novex 10%-20% Tris-glycine gels, 1.0-mm,
10-well (Invitrogen) and run for 2 hours at 125 V. After transfer by
electroblotting (200 mA for 2 hours) to Hybond-H Extra, nitrocellulose
membranes, 0.45 mm (Amersham Biosciences/GE Healthcare), the blots
were blocked with 5% skim milk in PBS-T (0.05% Tween-20 in 80mM
Na2HPO4, 20mM NaH2PO4, and 100mM NaCl, pH 7.5) and incubated
overnight at 4°C. The blots were washed 3 times in PBS-T, incubated for
1 hour with the primary antibody, washed again 3 times in PBS-T, and
incubated with HRP-conjugated secondary antibodies (P217, P260; Dako
or ab16349; Abcam; diluted 1:5000). Development of blots was done using
the enhanced chemiluminescence system (Amersham International) after
4 PBS-T washes. Digital photos were taken and analyzed by Fujifilm
LAS-3000 and Image Reader LAS-3000 (Fuji). Quantification of the bands
in the WBs was done with the Multi Gauge V3.0 analysis program (Fuji). In
brief, boxes were created around each band and a background box was
made in a reference area. The pixel intensities were measured and the mean
of the pixel intensity from the reference area was subtracted from each pixel
in the bands. The intensities of the bands were then analyzed with a
Mann-Whitney U test to find significant differences (P  .05).
“Housekeeping” proteins are often used as references to check for
proper analyses of the WBs because the expression of these proteins is
assumed to be at a constant level under varying conditions. However, there
is increasing evidence from proteomic studies that “housekeeping” proteins
such as actin, tubulin, and GAPDH may be inadequate as internal standards
because their expression can be affected by a large number of factors.19,21-23
Our present observations are in agreement with these findings, because we
found 2 often used “housekeeping” proteins, actin and GAPDH, to be
differentially expressed in tumor biopsies. Therefore, they were not
considered adequate as reference proteins in the present study. Instead, we
chose to normalize the WBs to the total protein concentration present in the
tumor sample. For this purpose, the protein concentration was measured
using a noninterfering protein assay (see “Determination of total protein
content”).
IHC and in situ hybridization
IHC staining was performed using 4-m paraffin-embedded tissue sections.
Gal-1, FoxP3, granzyme-B, CD68, CD163, and LMP-1 stainings were
performed on the Benchmark automated staining system (Ventana Medical
Systems). For PRDX1, the Xmatrx automated staining system (BioGenex
Laboratories) was used. The staining for PSME1 was performed manually.
Slides were incubated with the primary antibodies for 32 minutes (Gal-1,
PSME1, FoxP3, granzyme-B, CD68, CD163, and LMP-1) or 60 minutes
(PRDX1) at 37°C. For primary antibody detection, the Ventana Ultraview
DAB detection kit and the Dako Envision Flex visualization system were
used. Tissues from malignant melanoma (Gal-1), tonsil tissue (FoxP3 and
granzyme-B), colon (PSME1), lung (PRDX1), liver (CD68 and CD163),
and Epstein-Barr virus–positive (EBV) cHL specimens (LMP-1 and
EBER) were used as positive controls. The primary antibodies were omitted
in negative controls. For LMP-1 staining, the signal was enhanced with a
Ventana amplification kit. Slides were counterstained with hematoxylin.
Nonisotopic in situ hybridization for EBV-encoded RNAs 1 and 2 (EBER)
was performed and scored as described previously.24
TMA construction
TMA blocks containing triplicate 1-mm cores from each patient paraffin-
embedded sample were constructed with a manual tissue microarrayer
(Beecher Instruments) according to standard guidelines.25 Each block also
contained samples of normal lymph node, placenta, kidney, and liver tissue
as internal controls and guides.
Quantification of Gal-1 expression in HRS cells
Case in which  50% of the HRS cells reacted with the antibody were
considered positive. Intra-observer variation was estimated in 30 patients
and the match between readings was found to be excellent with an overall
agreement of 89%.
Quantification of Gal-1 expression in nonneoplastic bystander cells
Quantification of immunohistochemical stained sections was performed by
stereologic analysis using a light microscope equipped with a computer-
assisted stereology system (CAST; Visiopharm). The microscope had a
motorized stage controlled by a computer for systematic uniform random
sampling of fields of view. A Gal-1–positive cell profile in the tumor
microenvironment was defined as nuclear staining of any non-HRS cell in
the tumor microenvironment (eg, macrophages, plasma cells, lymphocytes,
or endothelial cells). A minimum of 100 Gal-1–positive cell profiles was
counted from each patient sample (median for the entire cohort: 232). Cell
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profiles were counted with a 40	 lens at a final screen magnification of
1423	 using a 2D unbiased counting frame.26 Areas containing either
necrosis or artifacts were ignored. To evaluate the intra-observer variation,
the Pearson correlation coefficients were calculated in a subset of patients
(n 30). The correlation coefficient was found to be 0.91 and, in accordance
with a cut-point between the third and fourth quartile, the percentage of correctly
classified samples was 93%. The numbers of FoxP3- and granzyme-B–positive
cell profiles per square millimeter were quantified in a similar manner. The
CD68 or CD163 volume fraction was determined by point counting with a
20	 lens at a total magnification of 739	.
Statistical analysis
Patient characteristics were compared using the Wilcoxon rank-sum test,
Kruskal-Wallis equality-of-populations rank test, and 
2 when appropriate.
The follow-up time was defined as the time from diagnosis to either last
follow-up or a given event. Event-free survival (EFS) was measured from
the date of diagnosis to either disease progression or relapse, discontinua-
tion of treatment for any reason, or censoring date. Overall survival (OS)
was measured from the date of diagnosis to the date of death for any reason
or censoring date. For correlation of patient survival and Gal-1 expression,
Figure 2. 2D-gel analysis. (A-B) Representative gels
(pH 3-10 IPG and pH 4-7 IPG) from 2D-PAGE. The
4-digit numbers are the specific spot numbers of the
proteins listed in Table 2. (C) Histograms of all identified
proteins displaying the spot intensities. Each patient is
represented by 1 column and columns are stacked accord-
ing to treatment response (favorable vs unfavorable
outcome).
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patients were grouped into quartiles. The quartile of patients with the
highest Gal-1 expression was also analyzed against the lower 3 quartiles
taken as one group. This corresponded to a cut point of 1825 cell
profiles/mm2, which was used throughout the data analysis. Survival was
estimated by the Kaplan-Meier method and compared using a log-rank test.
A Cox proportional multivariate model was used to assess the possible
association between Gal-1 and OS and EFS, while adjusting for those
factors that had a significance level .10 at the univariate level. Before the
Cox regression analysis, the assumption of proportional hazards was
assessed graphically. Correlation between continuous variables was deter-
mined using the Kendall correlation. Two-sided P  .05 was considered
statistically significant and P  .10 was considered as borderline signifi-
cant. All statistical analyses were done using STATA software Version 10.1.
Results
Identification of differentially expressed proteins using
2D-PAGE and LC-MS/MS
Figure 2 shows representative 2D gels from the pH 3-10 IPG and
pH 4-7 IPG experiments. In total, 37 protein spots were found to be
differentially expressed in patients with advanced-stage Hodgkin
lymphoma. All of these were excised and analyzed for protein
identification. Using LC-MS/MS and a subsequent search in the
Swiss-Prot Database, 23 spots resulted in clear protein identifica-
tion. Four of these spots contained more than one protein; for
example, spot 4302 contained both the Ig  chain C region and
actin. Moreover, some proteins were identified in more than one
spot (eg, PRDX1 in 2 spots: 8206 and 8208). Table 2 summarizes
the identification information, including protein name, accession
number, molecular weight, Mascot score, and function. Five of the
listed proteins were further validated by WB analysis.
Validation of proteomic analysis by WB
Figure 3 shows WB analysis of the 5 proteins differentially
expressed in the 2 patient cohorts: Gal-1, GNAI3, PRDX1, PSME1,
and desmoplakin. Integrative analysis confirmed the differential
expression of these 5 proteins in patient samples. However, Gal-1
was the only protein that was significantly up-regulated in treat-
ment refractory patients (P  .01). The remaining 4 proteins
showed either a significant (GNAI3, P  .0003; PRDX1, P  .02)
or a trend-like nonsignificant (PSME1, P  .11; desmoplakin,
P  .052) up-regulation in patients with favorable outcome.
Figure 3. Quantification of protein expression by Western blotting. (A) WBs of differentially expressed proteins. (B) Dot-plots demonstrating the band intensities according
to treatment outcome.
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Immunohistochemical localization of Gal-1, PSME-1, and
PRDX1 in the cHL microenvironment
Figure 4 illustrates representative immunohistochemical stainings
for Gal-1, PSME-1, and PRDX1. Cytoplasmic and nuclear Gal-1
labeling were found in HRS cells, lymphoma-associated macro-
phages and endothelial cells in line with previous reports12,13
(Figure 4A). Furthermore, we also noted a positive nuclear/
cytoplasmic reaction in some plasma cells. Most tumor-infiltrating
lymphoid cells were Gal-1 negative. PSME1 immunostaining
demonstrated a combined cytoplasmic/nuclear positivity in both
tumor and nonneoplastic by-stander cells (Figure 4B). PRDX1 was
also found to be weakly expressed by HRS cells. The signal
localization was primarily cytoplasmic. With regard to the tumor
microenvironment, PRDX1 was predominantly expressed in lym-
phoma-associated macrophages (Figure 4C).
Clinicopathologic features of TMA cohort patients
The main clinical and histopathologic features of the study cohort
are summarized in Table 3. The patient population had a median
age of 35 years and a male/female ratio of 1.8. The median
follow-up was 7 years (range: 0.2-18.6 years). The majority of the
patients (60%) had stage III-IV disease, whereas 40% presented
with a lower clinical stage (I-II) but with concomitant B symptoms
as a probable sign of more advanced disease. The large majority of
the patients in the study cohort (82%) had B-symptoms at
presentation and the median IPS score was 2. Approximately
one-third of the patients had EBV-positive tumors. The large
majority (84%) displayed histologic features consistent with the
nodular sclerosis subtype.
Correlation of Gal-1 expression in neoplastic and nonneoplastic
cells with demographic and clinicopathologic features
A total of 78 patients (55%) showed Gal-1 positivity in HRS cells.
Interestingly, we found that cases with a high expression of Gal-1
in HRS cells frequently presented with B symptoms at diagnosis
(P  .002). Gal-1 expression in HRS cells was correlated with
histologic subtype. Furthermore, with respect to the expression of
Gal-1 in nonneoplastic cells, only 1 significant correlation was
found: high expression of Gal-1 was correlated with the presence of
B symptoms (P  .03; Table 3).
Correlation of Gal-1 expression in neoplastic and
nonneoplastic cells with patient survival in Hodgkin lymphoma
Patient survival (OS as well as EFS) was correlated with age, with
higher survival in the group of patients  45 years. Several other
clinicopathologic parameters showed no correlation with survival. With
respect to Gal-1 expression, there was no correlation between Gal-1
expression in HRS cells and OS or EFS (results not shown). Interest-
ingly, a high Gal-1 expression in the tumor microenvironment was
significantly correlated with poor EFS (P .02; Table 4). Among the
younger, transplant-eligible patient population ( 61 years), the adverse
impact of a high number of Gal-1–positive cell profiles on outcome was
more pronounced. EFS and OS for low versus high Gal-1 expression
were 90% compared with 78% (P .007) for the former and 69%
compared with 49% (P .007) for the latter end point. Survival curves
are shown in Figure 5. In this younger patient population, high Gal-1
values retained their significant impact on EFS (P  .005) at the
multivariate level. The predictive value of Gal-1 expression in
younger patients ( 61 years) persisted also in terms of both EFS
and OS despite the concomitant presence of macrophage-related
parameters such as high CD68 (P values: .009 and .02, respec-
tively) or high CD163 expression (P values: .02 and .003,
respectively) in the Cox regression model.
Correlation between Gal-1 expression in the nonneoplastic
cells and tumor-infiltrating inflammatory cells of Hodgkin
lymphoma patients
We further examined the correlation between Gal-1 expression and
the tumor inflammatory infiltrate characteristic of cHL. With regard
to the tumor microenvironment, Gal-1 was positively correlated
with the level of macrophage marker expression, in particular the
M2 macrophage marker CD163 (P  .0007) and to a lesser extent
the pan-macrophage marker CD68 (P  .052). This result is
Figure 4. Representative immunohistochemical stainings of the differentially
expressed proteins Gal-1, PSME-1, and PRDX-1. (A) Gal-1 staining of a multi-
nuclear HRS cell (thick arrow). (B) PSME-1 staining of HRS cells (thick arrow) and
tumor-infiltrating cells. (C) PRDX1 staining showing a positive HRS cell (thick arrow)
among PRDX-1–positive macrophages (thin arrow). All magnifications are 400	.
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relevant in terms of the ability of Gal-1 to foster the differentiation
of alternatively activated macrophages and tolerogenic dendritic
cells.27-29 Furthermore, a significant correlation between Gal-1 and
granzyme B cytotoxic T lymphocytes was found (P  .02).
Conversely, no correlation with FoxP3 T-regulatory cells was
detected (P  .26) in spite of the abundant expression of Gal-1 in
FoxP3 T-regulatory cells.30
Discussion
The Human Genome Project has revealed that the number of
proteins in the human proteome exceeds by far the number of
protein-coding genes in the human genome ( 400 000 proteins
versus  30 000 genes).31 Because proteins are the functional end
product, it seems more appropriate to search for potential tumor
biomarkers at the protein level rather than at the gene level.
Previous studies in lymph nodes and lymphoma samples have
shown that the 2D gel-based proteomics approach was feasible and
reproducible.32 Furthermore, it was demonstrated that this tech-
nique yielded similar results, irrespective of whether fresh biopsies
or frozen samples that had been stored up to 1 year were used.
Subsequently, this methodology was applied to compare mantle
cell lymphoma samples and inflammatory lymph node tissue,
resulting in the identification of several differentially expressed
proteins.33 In our study, we were able to demonstrate the feasibility
of using archival whole-tumor frozen tissue from cHL patients for
proteomic analysis. Although some of these samples had been
stored for  10 years, they still yielded technically satisfactory
results. Proteomic-based expression profiles of the 2 patient groups
selected on the basis of their response to treatment successfully
identified proteins of prognostic value that were differentially
expressed between these 2 groups.
The glycan-binding protein Gal-1 has been previously impli-
cated as a modulator of cHL. Expression of this protein by Reed
Sternberg cells has been demonstrated to confer immune privilege
to cHL cells, creating an appropriate niche for tumor progression.
On the basis of gene-expression profiling, Gal-1 was found to be
overexpressed in HRS cell lines and its secretion favored a
Th2-type immune response characterized by high IL-4 and IL-13
secretion and promoted the expansion of CD4CD25FoxP3
regulatory T cells.12 Moreover, exposure to recombinant Gal-1
inhibited proliferation and IFN- secretion by EBV-specific T cells,11
and T cells specific for EBV-LMP1 were much more susceptible to
Gal-1–mediated immunosuppression than conventional T cells,34
suggesting a critical role for Gal-1 in compromising cHL-specific
immunity. Supporting these findings, Gal-1-deficient (Lgals1/)
mice were found to be highly susceptible to Th1- and Th17-
dependent inflammation compared with their wild-type counter-
parts.35 Subsequent studies have shown that Gal-1 expression is not
only seen in HRS cells, but is also abundant in the tumor
microenvironment.13 The latter observation was confirmed by our
Table 3. Correlation of demographic and clinicopathological parameters with Gal-1 expression in HRS cells and in the tumor
microenvironment
HRS Gal-1
Non-HRS Gal-1, cell
profile Gal-1
count/mm2
Characteristic Total no. % Gal-1 neg Gal-1 pos P† Median P‡
143
Age, y (n  143)
 45 91 64 46 45 .11 1361 .27
 45 52 36 19 33 1496
Sex (n  143)
Male 92 64 43 49 .68 1387 .30
Female 51 36 22 29 1361
Ann Arbor stage (n  143)
I-II 57 40 23 34 .32 1511 .62
III-IV 86 60 42 44 1358
B symptoms (n  143)
Yes 117 82 46 71 .002 1482 .03
No 26 18 19 7 1138
Bulky disease,> 10 cm (n  135)*
Yes 49 36 23 26 .76 1228 .20
No 86 64 38 48 1377
Histologic type (n  143)
NSI 78 55 37 41 .03 1523 .49
NSII 42 29 13 29 1302
MC 22 15 15 7 1387
cHL, NOS 1 1 0 1 1523
IPS (n  125)*
 2 68 54 36 32 .11 1369 .51
 2 57 46 22 35 1361
EBV status (n  143)
Positive 48 34 28 20 .03 1345 .54
Negative 95 66 37 58 1384
NSI indicates nodular sclerosis type I; NSII, nodular sclerosis type II; MC, mixed cellularity; NOS, not otherwise specified; and IPS, international prognostic score.
*Parameter not available in all 143 patients.
†
2 test.
‡Wilcoxon rank-sum test or Kruskal-Wallis equality-of-populations rank test where appropriate.
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study, although a correlation between Gal-1 expression and FoxP3
up-regulation could not be demonstrated at the level of primary
biopsies.
An important finding of the present study was the identification
by proteomic analysis of Gal-1 among the proteins that are
differentially expressed in treatment-refractory disease. This obser-
vation was further substantiated by immunohistochemical analysis,
which unambiguously showed a correlation between Gal-1 expres-
sion within the tumor microenvironment and poor clinical out-
come. This impact was much more evident among younger patients
( 61 years), and persisted for EFS after a multivariate analysis.
Considering the fact that Gal-1 is expressed in macrophages and
that macrophages have recently been shown by our group to predict
a poor prognosis,5,36,37 it seemed relevant to test whether the
adverse prognostic impact of Gal-1 also would persist in the
presence, within the Cox regression model, of parameters associ-
ated with the number of macrophages (ie, CD68 or CD163
positivity). The predictive value of Gal-1 expression in younger
patients ( 61 years) was retained in terms of both EFS and OS
despite the concomitant presence of high CD68 or high CD163
expression, suggesting that the prognostic impact of high Gal-1
expression is not a mere reflection of the number of macrophages in
the tumor tissue.
In addition to Gal-1, we identified in the pilot study PRDX1 and
GNAI3 among proteins that were substantially up-regulated in
patients with a favorable outcome. PRDX1 is a member of the
peroxiredoxin family of antioxidant enzymes, which reduces
hydrogen peroxide and alkyl hydroperoxides. In addition to its role
as an antioxidant, it has been shown to enhance the cytotoxicity of
natural killer cells.38 Interestingly, PRDX1-null mice develop
hemolytic anemia (due to the accumulation of reactive oxygen
species) and a variety of malignancies including lymphomas. For
this reason, it has been suggested that this protein plays an
antioxidant protective role and may function as a tumor suppressor.39
GNAI3 belongs to the guanine nucleotide-binding proteins
(G-proteins) that are important regulators of Akt-mediated cell
migration,40 a critical process that contributes to shaping the tumor
microenvironment. Many cytokines and chemoattractants signal
through the Akt/PKB pathway at the leading edge of migrating
cells.41 All differentially expressed proteins identified on the basis
of the proteomic analysis are currently being investigated in a
validation setting. Therefore, while the results of the validation
studies are pending, it is premature to formulate prognostic
statements with regard to these additional differentially expressed
proteins.
In summary, our study confirms the feasibility of using archival
frozen tissues from cHL patients for proteomic analysis. The
2 clinical groups analyzed showed relevant differences in their
protein expression profiles. Whereas the immunoregulatory glycan-
binding protein Gal-1 was up-regulated in patient subsets with
poorer outcome, PRDX1, a member of a family of antioxidant
enzymes, and GNAI3, a cell migration–associated protein, were
identified among proteins that were substantially up-regulated in
patients with a favorable outcome. In cHL (as in certain non-
Hodgkin lymphoma subtypes), there is now substantial evidence to
show that the tumor microenvironment plays an important role in
the biology and prognosis of the disease.42,43 Our study contributes
further evidence to support this hypothesis identifying Gal-1 as a
Table 4. Correlation of clinicopathological parameters and Gal-1 expression in nonneoplastic cells with survival
OS EFS
Characteristic 5-year OS, % HR 95% CI P 5-Year EFS, % HR 95% CI P
Age, y
 45 92 1 ref  .001 64 1 ref .005
 45 57 5.36 2.86-10.06 48 1.91 1.21-3.01
Sex
Male 78 1 ref .16 55 1 ref .09
Female 80 0.64 0.35-1.20 63 0.66 0.41-1.07
Ann Arbor stage
I-II 80 1 ref .87 63 1 ref .33
III-IV 77 0.95 0.53-1.72 55 1.26 0.79-2.01
B symptoms
No 79 1 ref .45 52 1 ref .84
Yes 79 1.37 0.61-3.07 60 0.94 0.54-1.66
Bulky disease> 10 cm
No 82 1 ref .15 60 1 ref .27
Yes 71 1.57 0.85-2.92 54 1.31 0.81-2.11
Histologic type
NSI 84 1 ref .21 64 1 ref .13
NSII 70 1.43 0.72-2.82 56 1.19 0.69-2.04
MC 77 1.11 0.45-2.72 49 1.47 0.77-2.79
cHL, NOS 33 4.50 1.05-19.35 0 3.77 1.16-12.3
EBV status
Negative 78 1 ref .77 57 1 ref .86
Positive 79 1.09 0.59-2.03 60 0.96 0.59-1.55
Gal-1 (all)
Low 81 1 ref .06 62 1 ref .02
High 72 1.87 0.97-3.60 45 1.85 1.11-3.09
Gal-1< 61 y
Low 90 1 ref 69 1 ref
High 78 3.25 1.38-7.67 .007 49 2.34 1.26-4.36 .007
OS indicates overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval; ref, reference; NSI, nodular sclerosis type I; NSII, nodular sclerosis type II;
MC, mixed cellularity; NOS, not otherwise specified; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; and IPS, international prognostic score.
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potential novel biomarker that may be useful in the prognostic and
predictive analysis of cHL. It also underlines the advantages of
proteomics in providing important clues to identifying new thera-
peutic, diagnostic, and prognostic targets in hematologic
malignancies.
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